Paper2890636
The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions.
Boucek RJ and 5 others. J Biol Chem, 1987. Cited by 137 papers, by iCite.
Cite this record
ConductScience Library. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. Papers, record 2890636. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2890636
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions.
- PubMed
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenosine Triphosphatases | Major topic |
| Doxorubicin | Major topic |
| Myocardium | Major topic |
| Sarcoplasmic Reticulum | Major topic |
| 5'-Nucleotidase | |
| Animals | |
| Ca(2+) Mg(2+)-ATPase | |
| Calcium-Transporting ATPases | |
| Dogs | |
| Heart | |
| Kinetics | |
| Nucleotidases | |
| Proton-Translocating ATPases | |
| Sodium-Potassium-Exchanging ATPase |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| HL 28711 | NHLBI NIH HHS | United States | R23HL028711 | PubMed and NIH | NIH RePORTER |
| HL 32711 | NHLBI NIH HHS | United States | R01HL032711 | PubMed and NIH | NIH RePORTER |
| HL 33060 | NHLBI NIH HHS | United States | R01HL033060 | PubMed and NIH | NIH RePORTER |
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 137 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41252081 | TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16). | Clin Pharmacokinet | 2026 | https://conductscience.org/library/papers/41252081 | PubMed |
| 40481868 | Daunorubicin and its hydroxy metabolite in cardiomyocytes: insights into cellular kinetics, toxicity, DNA damage, and dexrazoxane-induced cardioprotection. | Arch Toxicol | 2025 | https://conductscience.org/library/papers/40481868 | PubMed |
| 38469202 | Protective effect of coenzyme Q10 against doxorubicin-induced cardiotoxicity: Scoping review article. | Saudi Pharm J | 2024 | https://conductscience.org/library/papers/38469202 | PubMed |
| 38175295 | In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases. | Arch Toxicol | 2024 | https://conductscience.org/library/papers/38175295 | PubMed |
| 37175180 | In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics. | Molecules | 2023 | https://conductscience.org/library/papers/37175180 | PubMed |
| 34926288 | Intracellular Water Lifetime as a Tumor Biomarker to Monitor Doxorubicin Treatment via FFC-Relaxometry in a Breast Cancer Model. | Front Oncol | 2021 | https://conductscience.org/library/papers/34926288 | PubMed |
| 33917090 | Novel Pyrimidine Derivatives as Potential Anticancer Agents: Synthesis, Biological Evaluation and Molecular Docking Study. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33917090 | PubMed |
| 33574985 | Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies. | Oxid Med Cell Longev | 2021 | https://conductscience.org/library/papers/33574985 | PubMed |
| 33526869 | Label-free spectral imaging to study drug distribution and metabolism in single living cells. | Sci Rep | 2021 | https://conductscience.org/library/papers/33526869 | PubMed |
| 33063185 | Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. | Eur Radiol | 2021 | https://conductscience.org/library/papers/33063185 | PubMed |
| 31955137 | Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified. | Drug Metab Dispos | 2020 | https://conductscience.org/library/papers/31955137 | PubMed |
| 30862114 | The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells. | Biomolecules | 2019 | https://conductscience.org/library/papers/30862114 | PubMed |
| 30677473 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. | Pharmacol Ther | 2019 | https://conductscience.org/library/papers/30677473 | PubMed |
| 29670334 | Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. | Drug Des Devel Ther | 2018 | https://conductscience.org/library/papers/29670334 | PubMed |
| 29161764 | Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. | Br J Pharmacol | 2018 | https://conductscience.org/library/papers/29161764 | PubMed |
| 28283780 | Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents. | Invest New Drugs | 2017 | https://conductscience.org/library/papers/28283780 | PubMed |
| 27447545 | Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. | Br J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/27447545 | PubMed |
| 27197003 | Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. | Br J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/27197003 | PubMed |
| 26975227 | Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. | Pharmacogenomics J | 2017 | https://conductscience.org/library/papers/26975227 | PubMed |
| 26491536 | Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. | Oxid Med Cell Longev | 2015 | https://conductscience.org/library/papers/26491536 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2890636
GET https://conductscience.org/api/papers/v1/2890636/cited_by?page=2